REVENUE (Tables)

3 Months Ended

Mar. 31, 2024

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the three months ended March 31, 2024, was as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2023	$	32.7	$	7.5	$	0.7	$	40.9
Plus, credit loss expense	2.4		—		—		2.4
Less, write offs	0.9		0.1		—		1.0
Balance as of March 31, 2024	$	34.2	$	7.4	$	0.7	$	42.3

Contract with Customer, Asset and Liability [Table Text Block]

	March 31, 2024		December 31, 2023
Dx accounts receivable	$	1,260.9	$	1,135.2
BLS accounts receivable	857.0		810.8
Less BLS allowance for doubtful accounts	(34.2)		(32.7)
Accounts receivable	$	2,083.7	$	1,913.3
Gross unbilled services	$	127.8	$	192.9
Less reserve for unbilled services	(7.4)		(7.5)
Unbilled services	$	120.4	$	185.4
Unearned revenue	$	377.5	$	421.7

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three months ended March 31, 2024, and 2023, were as follows:

	For the Three Months Ended March 31, 2024								For the Three Months Ended March 31, 2023
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	25	%	—	%	—	%	25	%	25	%	—	%	—	%	25	%
Patients	10	%	—	%	—	%	10	%	9	%	—	%	—	%	9	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	35	%	—	%	—	%	35	%	36	%	—	%	—	%	36	%
Total Dx revenues by payer	78	%	—	%	—	%	78	%	78	%	—	%	—	%	78	%
BLS
Pharmaceutical, biotechnology and medical device companies	9	%	9	%	4	%	22	%	9	%	9	%	4	%	22	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the U.S. were $2,654.6 (83.6%) and $2,557.4 (84.2%) for the three months ended March 31, 2024, and 2023, respectively.